|Bid||1.500 x 1000|
|Ask||1.580 x 100|
|Day's Range||1.680 - 1.740|
|52 Week Range||1.340 - 5.160|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.79|
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trevena, ...
CHESTERBROOK, Pa., Feb. 02, 2018-- Trevena, Inc. today announced the promotion of Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Operating ...
The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.
Trevena Inc. shares jumped in the extended session Tuesday after the biotech company said the Food and Drug Administration accepted for review a marketing application for its opioid-replacement painkiller. ...
CHESTERBROOK, Pa., Jan. 02, 2018-- Trevena, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company’ s New Drug Application for OLINVO™ Injection. The Company expects that ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Chester County biopharmaceutical company Trevena Inc. is cutting 21 jobs and halting its investments in early-stage research under a restructuring to focus its resources on its lead new drug candidate. The workforce reduction represents 30 percent of the Chesterbook, Pa., company's staff. Trevena's immediate focus will be on the potential approval and commercialization of Olinvo, its new drug candidate under development as a potential treatment to manage moderate-to-severe acute pain.
The King Of Prussia, Pennsylvania-based company said it had a loss of 35 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...